Savant Capital LLC Sells 2,784 Shares of Stryker Corporation $SYK

Savant Capital LLC decreased its holdings in shares of Stryker Corporation (NYSE:SYK) by 30.8% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,260 shares of the medical technology company’s stock after selling 2,784 shares during the period. Savant Capital LLC’s holdings in Stryker were worth $2,200,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Moors & Cabot Inc. boosted its position in shares of Stryker by 0.4% during the 4th quarter. Moors & Cabot Inc. now owns 9,765 shares of the medical technology company’s stock valued at $3,432,000 after purchasing an additional 41 shares in the last quarter. Intech Investment Management LLC boosted its position in shares of Stryker by 36.7% during the 4th quarter. Intech Investment Management LLC now owns 12,011 shares of the medical technology company’s stock valued at $4,222,000 after purchasing an additional 3,227 shares in the last quarter. CFS Investment Advisory Services LLC boosted its position in shares of Stryker by 75.4% during the 4th quarter. CFS Investment Advisory Services LLC now owns 1,114 shares of the medical technology company’s stock valued at $392,000 after purchasing an additional 479 shares in the last quarter. Godfrey Financial Associates Inc. bought a new stake in shares of Stryker during the 4th quarter valued at about $26,000. Finally, Kingsview Wealth Management LLC boosted its position in shares of Stryker by 0.3% during the 4th quarter. Kingsview Wealth Management LLC now owns 14,055 shares of the medical technology company’s stock valued at $4,940,000 after purchasing an additional 46 shares in the last quarter. Institutional investors own 77.09% of the company’s stock.

Insider Activity

In other news, Director Ronda E. Stryker sold 310,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total value of $96,791,300.00. Following the transaction, the director owned 1,924,880 shares in the company, valued at $601,005,282.40. This trade represents a 13.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP M Kathryn Fink sold 5,220 shares of the firm’s stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $283.85, for a total value of $1,481,697.00. Following the completion of the transaction, the vice president owned 13,137 shares in the company, valued at $3,728,937.45. This represents a 28.44% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 323,264 shares of company stock worth $100,659,489 over the last 90 days. 4.60% of the stock is currently owned by corporate insiders.

Stryker Stock Up 0.2%

SYK stock opened at $305.73 on Monday. The company has a market cap of $117.21 billion, a P/E ratio of 35.39, a price-to-earnings-growth ratio of 1.92 and a beta of 0.78. Stryker Corporation has a fifty-two week low of $281.00 and a fifty-two week high of $404.87. The stock’s 50 day simple moving average is $321.82 and its 200 day simple moving average is $348.10. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.25 and a current ratio of 2.11.

Stryker (NYSE:SYK) last posted its earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). Stryker had a net margin of 13.20% and a return on equity of 23.42%. The company had revenue of $6.02 billion during the quarter, compared to the consensus estimate of $6.34 billion. During the same quarter in the prior year, the business earned $2.84 EPS. The firm’s revenue for the quarter was up 2.6% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. On average, research analysts expect that Stryker Corporation will post 14.98 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Tuesday, June 30th will be issued a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.2%. The ex-dividend date is Tuesday, June 30th. Stryker’s dividend payout ratio (DPR) is currently 40.74%.

Wall Street Analyst Weigh In

Several brokerages recently commented on SYK. Canaccord Genuity Group cut their target price on Stryker from $435.00 to $400.00 and set a “buy” rating on the stock in a research report on Friday, May 1st. JPMorgan Chase & Co. dropped their price target on Stryker from $445.00 to $400.00 and set an “overweight” rating on the stock in a research note on Friday, May 1st. Citigroup dropped their price target on Stryker from $420.00 to $385.00 and set a “buy” rating on the stock in a research note on Tuesday, April 7th. UBS Group dropped their price target on Stryker from $400.00 to $380.00 and set a “neutral” rating on the stock in a research note on Tuesday, March 17th. Finally, Sanford C. Bernstein set a $410.00 price target on Stryker in a research note on Friday, May 1st. Sixteen equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat, Stryker currently has an average rating of “Moderate Buy” and a consensus target price of $395.48.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.